[HTML][HTML] Transcriptional evidence for the role of chronic venlafaxine treatment in neurotrophic signaling and neuroplasticity including also glutatmatergic-and insulin …
V Tamási, P Petschner, C Adori, E Kirilly, RD Ando… - PloS one, 2014 - journals.plos.org
PloS one, 2014•journals.plos.org
Objectives Venlafaxine (VLX), a serotonine-noradrenaline reuptake inhibitor, is one of the
most commonly used antidepressant drugs in clinical practice for the treatment of major
depressive disorder (MDD). Despite being more potent than its predecessors, similarly to
them, the therapeutical effect of VLX is visible only 3–4 weeks after the beginning of
treatment. Furthermore, recent papers show that antidepressants, including also VLX,
enhance the motor recovery after stroke even in non depressed persons. In the present …
most commonly used antidepressant drugs in clinical practice for the treatment of major
depressive disorder (MDD). Despite being more potent than its predecessors, similarly to
them, the therapeutical effect of VLX is visible only 3–4 weeks after the beginning of
treatment. Furthermore, recent papers show that antidepressants, including also VLX,
enhance the motor recovery after stroke even in non depressed persons. In the present …
Objectives
Venlafaxine (VLX), a serotonine-noradrenaline reuptake inhibitor, is one of the most commonly used antidepressant drugs in clinical practice for the treatment of major depressive disorder (MDD). Despite being more potent than its predecessors, similarly to them, the therapeutical effect of VLX is visible only 3–4 weeks after the beginning of treatment. Furthermore, recent papers show that antidepressants, including also VLX, enhance the motor recovery after stroke even in non depressed persons. In the present, transcriptomic-based study we looked for changes in gene expressions after a long-term VLX administration.
Methods
Osmotic minipumps were implanted subcutaneously into Dark Agouti rats providing a continuous (40 mg/kg/day) VLX delivery for three weeks. Frontal regions of the cerebral cortex were isolated and analyzed using Illumina bead arrays to detect genes showing significant chances in expression. Gene set enrichment analysis was performed to identify specific regulatory networks significantly affected by long term VLX treatment.
Results
Chronic VLX administration may have an effect on neurotransmitter release via the regulation of genes involved in vesicular exocytosis and receptor endocytosis (such as Kif proteins, Myo5a, Sv2b, Syn2 or Synj2). Simultaneously, VLX activated the expression of genes involved in neurotrophic signaling (Ntrk2, Ntrk3), glutamatergic transmission (Gria3, Grin2b and Grin2a), neuroplasticity (Camk2g/b, Cd47), synaptogenesis (Epha5a, Gad2) and cognitive processes (Clstn2). Interestingly, VLX increased the expression of genes involved in mitochondrial antioxidant activity (Bcl2 and Prdx1). Additionally, VLX administration also modulated genes related to insulin signaling pathway (Negr1, Ppp3r1, Slc2a4 and Enpp1), a mechanism that has recently been linked to neuroprotection, learning and memory.
Conclusions
Our results strongly suggest that chronic VLX treatment improves functional reorganization and brain plasticity by influencing gene expression in regulatory networks of motor cortical areas. These results are consonant with the synaptic (network) hypothesis of depression and antidepressant-induced motor recovery after stroke.
PLOS